Ken Blount, PhD, CSO Rebiotix Inc., A Ferring Company
Download the presentation (1 MB)
2022 National C. diff Advocacy Summit
May 1 – 2, 2022
Washington, D.C.
Summary
- Every person carries an extensive and diverse community of microbes that influence daily health
- The community of healthy human bacterial microbiota can be disrupted by antibiotics, leading to C. diff infections and recurrent C. diff infections
- Investigational live biotherapeutics aim to reduce recurrent C. diff infections
- In multiple clinical trials RBX2660 clinically reduced recurrent C. diff infections and treatment was associated with a shift in microbiome and metabolite compositions, demonstrating the potential of microbiota-based live therapies to address disease